Trials / Completed
CompletedNCT00545129
A Study Of Tanezumab as Add-On Therapy to Opioid Medication In Patients With Pain Due To Cancer That Has Spread To Bone
PHASE II RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER EFFICACY AND SAFETY STUDY OF TANEZUMAB AS ADD-ON THERAPY TO OPIOID MEDICATION IN PATIENTS WITH PAIN DUE TO BONE METASTASES
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 59 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to investigate the safety and efficacy of tanezumab in combination with opioids in treating pain due to cancer that has spread to bone.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tanezumab 10 mg IV | Single IV infusion of 10 mg tanezumab on Day 1. Maintained on baseline opioid regimen. |
| DRUG | IV Placebo for tanezumab | Single IV infusion of placebo for tanezumab on Day 1. Maintained on baseline opioid regimen. |
Timeline
- Start date
- 2009-04-29
- Primary completion
- 2011-12-24
- Completion
- 2012-02-07
- First posted
- 2007-10-17
- Last updated
- 2021-06-18
- Results posted
- 2021-06-18
Locations
39 sites across 13 countries: United States, Austria, Bosnia and Herzegovina, Croatia, France, Hungary, India, Latvia, Mexico, Peru, Poland, Slovakia, South Korea
Source: ClinicalTrials.gov record NCT00545129. Inclusion in this directory is not an endorsement.